NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 10th September

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Becky Pennington Present for all items
4. Dominic Pivonka Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Ian Bernstein Present for all items
7. Dr Justin Daniels Present for all items
8. Dr Mohit Sharma Present for all items
9. Dr Peter Baker-Gulliver Items 1.1 to 4.2.2
10. Dr Ravi Ramessur Present for all items
11. Dr Steve Edwards Present for all items
12. Hugo Pedder Items 1.1 to 6.2.2
13. Jaqueline Tomlinson Present for all items
14. Mario Ganau Items 1.1 to 6.1.3
15. Min Ven Teo Items 1.1 to 5.2.2
16. Mohamad Farhat Items 1.1 to 5.2.2
17. Professor G.J. Melendez-Torres Present for all items
18. Youssof Oskrochi Present for all items
19. Carole Pitkeathley Items 1.1 to 6.1.3
20. Stella O’Brien Present for all items
21. Paul Caulfield Items 5.1 to 6.1.3
22. Michael Chambers Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.2.2

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Sharlene Ting, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Louise Jones, Administrator Items 1.1 to 4.2.2

Ian Watson, Associate Director Items 5.1 to 5.2.2

Leena Issa, Project Manager Items 5.1 to 5.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Samuel Slayen, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Rachel Williams, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Ishbel McCallum, Administrator Items 5.1 to 5.2.2

Janet Robertson, Associate Director Items 6.1 to 6.2.2

Jeniffer Upton, Project Manager Items 6.1 to 6.2.2

Vicky Kelly, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Victoria Gillis Elliott, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

Marcia Miller, Administrator Items 6.1 to 6.2.2

External assessment group representatives present

Dr Jonathan Shepherd, Southampton HTA Centre (SHTAC) Items 1.1 to 4.1.3

Professor Joanne Lord, Southampton HTA Centre (SHTAC) Items 1.1 to 4.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Items 6.1 to 6.1.3

Bram Ramaekers, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Items 6.1 to 6.1.3

Kate Ren, DSU – Sheffield Items 6.1 to 6.1.3

Jessica Forsyth, DSU – Sheffield Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Peter Clark, CDF Clinical Lead, nominated by NHSE Present for all items

Eleanor Pearce Willis, Policy Manager, patient expert nominated by Breast Cancer Now

Items 1.1 to 4.1.3

Kirstin Spencer, Patient Advocate, patient expert nominated by METUPUK

Items 1.1 to 4.1.3

Prof Mark Beresford, Consultant Clinical Oncologist, clinical expert nominated by Menarini Stemline Items 1.1 to 4.1.3

Dr Mukesh Bindlish Mukesh, Consultant Clinical Oncologist, clinical expert nominated by Menarini Stemline Items 1.1 to 4.1.3

Jo Gumb, Patient Expert, nominated by OcuMel Items 6.1 to 6.1.3

Victoria Jones, Patient Expert, nominated by OcuMel Items 6.1 to 6.1.3

Rumana Hussain, Clinical Expert, nominated by Royal College of Pathologists

Items 6.1 to 6.1.3

Dr Paul Nathan, Clinical Expert, nominated by Immunocore Items 6.1 to 6.1.3

Dr Joseph Sacco, Clinical Expert, nominated by Immunocore

Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Richard Ballerand, Craig Buckley, Patrick De Barr and Alan Thomas.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 13th August.

### Appraisal of Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Menarini Stemline.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11263).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Mohammed Farhat (lay and clinical lead) and Hugo Pedder (cost lead).
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11263>.

### Appraisal of Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11197).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fotheringham.
  2. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11197>.

### Appraisal of Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Immunocore.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10428).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fotheringham.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10428>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 9th October and will start promptly at 9:00.